Press release

Siemens Healthineers shows resilient performance despite COVID-19 pandemic

Siemens Healthineers AG today announced its results for the third quarter of fiscal year 2020 that ended June 30, 2020.

Q3 Fiscal Year 2020

  • Revenue down 6.9% year-over-year on a comparable basis due to COVID-19
  • Comparable revenue decline of 3.3% in Imaging, Advanced Therapies with comparable decline of 1.8%
  • Service with slight comparable revenue growth, stabilizing business
  • Equipment book-to-bill ratio at 0.94
  • Diagnostics with comp. revenue decline of 15.9% due to lower testing for routine care, significantly impacting profitability
  • Adjusted EBIT margin at 13.9%, 120 bps below prior-year quarter
  • Adjusted basic earnings per share down 21% to €0.30
  • Q3 free cash flow increases 48% year-over-year to €336 million
  • Comparable revenue growth expected to be broadly flat in fiscal year 2020; adjusted basic earnings per share expected to be between €1.54 and €1.62. This is based on the assumption that the current business environment will not deteriorate again

Bernd Montag, CEO of Siemens Healthineers AG:
"The Siemens Healthineers team has been making an extraordinary contribution to overcoming this historic crisis for months – at our customers’ sites, in production, at our locations around the world and through rapid innovation. The development in the third quarter underscores the resilience of our business. For the fourth quarter, we are anticipating a significant improvement of our business performance compared to the third quarter."

Link to the related press feature

Siemens Healthineers 2019

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion.